This immune regulation function of KRAS-mutations may improve tumor cell survival in the brain, but it also makes NSCLC BMs with KRAS-mutations more susceptible to treatment with immune checkpoint inhibitors (ICIs) [88]. The gene discussed is KRAS; the disease is neoplasm.